Psilocybin's strongest clinical signal isn't antidepressant. It may never have been.
Serotonin is increasingly understood as a neuromodulator of meaning: the sense that our lives have a thread, that our goals are worth pursuing, that what we do matters. Dopamine moves us toward rewards. Serotonin, broadly speaking, tells us whether those rewards are worth wanting. The distinction from mood regulation sounds abstract. It has real clinical consequences.
Psilocybin acts primarily at the 5-HT2A receptor, and what it appears to do is make rigid beliefs more flexible: patients can suddenly see their situation differently, sometimes dramatically so, after a single session. This is the core claim of the REBUS model (Carhart-Harris & Friston, Pharmacol Rev, 2019): 5-HT2A agonism relaxes the weight the brain places on entrenched beliefs, allowing new perspectives to emerge.
Stephen Ross's 2021 paper in ACS Pharmacological and Translational Science offers the clearest clinical answer we currently have. In cancer patients receiving psilocybin-assisted psychotherapy, Ross found large reductions in loss of meaning that emerged two weeks after treatment and held at follow-ups extending to four and a half years (Ross et al., 2021). Suicidal ideation fell too, and fell fast, within eight hours of dosing (Ross et al., 2021). Ross's point is that this speed doesn't fit an antidepressant story, which takes weeks. It fits a meaning story, where a single experience can reframe everything.
“Psilocybin is not primarily an antidepressant. It is a treatment for loss of meaning. And we don't have a diagnostic category for that yet.”
Depression and demoralization are not the same thing. Depression involves anhedonia, disrupted sleep, flattened affect. Demoralization is something more specific: the sense that one's actions have no purpose, that the future is unnavigable, that there is no story worth continuing. Ross's data doesn't prove that psilocybin works through meaning-making rather than mood. But the signal is too specific and too durable to be a generic antidepressant effect. It points somewhere.
The regulatory problem is that this somewhere has no clean address. Demoralization syndrome has been recognized in ICD-11, but it remains absent as a standalone indication from DSM-5-TR. The FDA works from DSM categories. So any sponsor trying to develop psilocybin for this indication faces a nosological gap the agency isn't currently equipped to adjudicate. Ross's own trials enrolled patients under adjustment disorder and cancer-related depression: proxies that capture part of the picture but not all of it.
That gap is also an opening. If you're willing to argue that demoralization is its own indication — and the ICD-11 gives you a legitimate foothold to do that — you're filing into a space with no approved treatments and data already pointing your way. The most parsimonious reading of Ross's data is that psilocybin is not primarily an antidepressant. It is a treatment for loss of meaning. And we don't have a diagnostic category for that yet.
References:
- Carhart-Harris, R.L. & Friston, K.J. (2019). REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacological Reviews, 71(3), 316–344.
- Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R.J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., & Mennenga, S.E. (2021). Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacology & Translational Science, 4(2), 553–562.
- Fava, M., Sorg, E., Jacobs, J.M., Leadbetter, R., & Guidi, J. (2023). Distinguishing and Treating Demoralization Syndrome in Cancer: A Review. General Hospital Psychiatry, 85, 185–190.